إعلان
إعلان

IMDX

I

Insight Molecular Diagnostics Inc. Common Stock

7.48
USD
برعاية
-0.02
-0.23%
٠٨ يناير, ١٦:٠٠ UTC -5
مغلق
exchange

بعد الإغلاق

7.58

+0.09
+1.23%

تقارير أرباح IMDX

النسبة الإيجابية المفاجئة

IMDX تفوق 15 من 40 آخر التقديرات.

38%

التقرير التالي

بيانات التقرير القادم
٢٣ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$295.80K
/
-$0.24
التغير الضمني من Q3 25 (Revenue/ EPS)
+13.77%
/
-29.41%
التغير الضمني من Q4 24 (Revenue/ EPS)
-80.09%
/
-87.56%

Insight Molecular Diagnostics Inc. Common Stock earnings per share and revenue

On ١٠ نوفمبر ٢٠٢٥, IMDX reported earnings of -0.34 USD per share (EPS) for Q3 25, missing the estimate of -0.21 USD, resulting in a -58.95% surprise. Revenue reached 260.00 ألف, compared to an expected 289.68 ألف, with a -10.25% difference. The market reacted with a +10.66% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 المحللين forecast an EPS of -0.24 USD, with revenue projected to reach 295.80 ألف USD, implying an نقصان of -29.41% EPS, and زيادة of 13.77% in Revenue from the last quarter.
الأسئلة الشائعة
For Q3 2025, Insight Molecular Diagnostics Inc. Common Stock reported EPS of -$0.34, missing estimates by -58.95%, and revenue of $260.00K, -10.25% below expectations.
The stock price moved up 10.66%, changed from $6.80 before the earnings release to $7.53 the day after.
The next earning report is scheduled for ٢٣ مارس ٢٠٢٦.
Based on 6 المحللين, Insight Molecular Diagnostics Inc. Common Stock is expected to report EPS of -$0.24 and revenue of $295.80K for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان